-
Electronic (PDF)
-
Site License
-
Enterprisewide
InterMed Discovery GmbH - Product Pipeline Review - H2 2011
Global Markets Direct, November 2011, Pages: 33
InterMed Discovery GmbH – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “InterMed Discovery GmbH - Product Pipeline Review - H2 2011” provides data on the InterMed Discovery GmbH’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, InterMed Discovery GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from InterMed Discovery GmbH and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- InterMed Discovery GmbH - Brief InterMed Discovery GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of InterMed Discovery GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of InterMed Discovery GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the InterMed Discovery GmbH’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate InterMed Discovery GmbH’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of InterMed Discovery GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the InterMed Discovery GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with InterMed Discovery GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of InterMed Discovery GmbH and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of InterMed Discovery GmbH; InterMed Discovery GmbH - Key Therapeutics; InterMed Discovery GmbH - Pipeline Overview and Promising Molecules; InterMed Discovery GmbH - News; InterMed Discovery GmbH - Latest Updates; InterMed Discovery GmbH - Pipeline; InterMed Discovery GmbH - Discontinued/Dormant Projects
List of Tables
List of Figures
InterMed Discovery GmbH Snapshot
InterMed Discovery GmbH Overview
Key Information
Key Facts
InterMed Discovery GmbH – Research and Development Overview
Key Therapeutic Areas
InterMed Discovery GmbH – Pipeline Review
Pipeline Products by Stage of Development
InterMed Discovery GmbH – Pipeline Products Glance
InterMed Discovery GmbH–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
InterMed Discovery GmbH – Drug Profiles
IMD 009425
Product Description
Mechanism of Action
R&D Progress
IMD 014591
Product Description
Mechanism of Action
R&D Progress
IMD 015213
Product Description
Mechanism of Action
R&D Progress
IMD 020102
Product Description
Mechanism of Action
R&D Progress
IMD 021365
Product Description
Mechanism of Action
R&D Progress
IMD 026259
Product Description
Mechanism of Action
R&D Progress
InterMed Discovery GmbH – Pipeline Analysis
InterMed Discovery GmbH – Pipeline Products by Therapeutic Class
InterMed Discovery GmbH - Pipeline Products By Target
InterMed Discovery GmbH – Pipeline Products by Molecule Type
InterMed Discovery GmbH - Dormant Projects
InterMed Discovery GmbH – Locations And Subsidiaries
Head Office
Recent Developments
Jan 20, 2011: InterMed Discovery Receives Michael J. Fox Foundation Award For IMD-026259
Aug 05, 2008: InterMed Discovery Achieves Proof-Of-Principle For IMD-026260
Financial Deals Landscape
InterMed Discovery GmbH, Deals Summary
InterMed Discovery GmbH, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
InterMed Discovery Acquires Microbial Source For Omega-3 Fatty Acid From University Of Saarland
Partnerships
BioFocus Enters Into Co-Marketing Agreement With InterMed Discovery
InterMed Enters Into Co Development Agreement With Axxam
InterMed Enters Into Co-Development Agreement With Biotropics
Cognis Enters Into Agreement With InterMed
Licensing Agreements
Cognis Enters Into Licensing Agreement With InterMed
Acquisition
InterMed Discovery Acquires Minority Stake In Biotropics Malaysia
Cognis Acquires InterMed Discovery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
InterMed Discovery GmbH – Pipeline by Therapy Area and Indication, H2 2011
InterMed Discovery GmbH – Pipeline by Stage of Development, H2 2011
InterMed Discovery GmbH - Pipeline By Therapeutic Class, H2 2011
InterMed Discovery GmbH - Pipeline By Target, H2 2011
InterMed Discovery GmbH – Pipeline By Molecule Type, H2 2011
InterMed Discovery GmbH - Dormant Developmental Projects, 2010
InterMed Discovery GmbH, Deals Summary
InterMed Discovery Acquires Microbial Source For Omega-3 Fatty Acid From University Of Saarland
BioFocus Enters Into Co-Marketing Agreement With InterMed Discovery
InterMed Enters Into Co Development Agreement With Axxam
InterMed Enters Into Co-Development Agreement With Biotropics
Cognis Enters Into Agreement With InterMed
Cognis Enters Into Licensing Agreement With InterMed
InterMed Discovery Acquires Minority Stake In Biotropics Malaysia
Cognis Acquires InterMed Discovery
List of Figures
InterMed Discovery GmbH – Pipeline by Therapy Area and Indication, H2 2011
InterMed Discovery GmbH – Pipeline by Stage of Development, H2 2011
InterMed Discovery GmbH – Pipeline By Therapeutic Class, H2 2011
InterMed Discovery GmbH - Pipeline By Target, H2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
